Intel's $20B Equity Raise Signals Dilution Risk Outweighing Product Recovery

What happened

Intel plans to issue 210.5 million shares at $95 each, raising roughly $20 billion in fresh equity, and the stock fell sharply on the news. The offering adds more than 4% to the share count, compounding the dilution already flagged from government-linked shares and derivative liabilities. While Intel’s product business is rebounding—Q2 revenue rose 25% and DCAI surged 59%—external foundry revenue was just $293 million, so the recovery is still mostly internal. Proceeds likely fund a capex bill that management has guided above $20 billion for 2026 and “significantly higher” in 2027, but selling stock at a discount to recent prices underscores how expensive the foundry ambition has become. Investors now face a trade-off: a genuine product turnaround versus a rising share count that dilutes per-share gains unless external foundry wins arrive soon.

Implication

Near term, the stock will grapple with an overhang from the offering’s size and the $95 anchor price, which could cap recovery rallies. The dilution reduces per-share earnings and free cash flow, making an already rich valuation even less compelling on a forward basis. For the thesis to hold, Intel must now show that the proceeds accelerate a path to meaningful external foundry revenue—otherwise, it’s simply financing more cash burn. Failure to announce a named 18A or 14A customer within the next six to nine months would turn this raise into a costly strategic misstep. If the funds instead catalyze a critical customer win, the dilution could be offset by a much larger equity value later, but that scenario remains unproven.

Thesis delta

The $20 billion offering materially raises dilution risk, tilting the probability toward the bear case and lowering the margin of safety. It adds urgency to the foundry commercialization timeline, because without external customer proof, the larger share count will permanently impair per-share returns. Our WAIT rating stands, but the attractive entry is under review below $85 given the bigger float and heightened execution risk.